Anti-protozoal Effect of Steroid Hormone 20-hydroxyecdysone
NCT04827537
Digestive System Diseases, Gastrointestinal Diseases
Tashkent, Uchtepa, Uzbekistan
View Trial DetailsNCT Number: NCT06533696
The present study was done to evaluate the efficacy of Human anti Giardia lamblia antibody (ELISA) kitst in comparison to direct microscopy in the diagnosis of G. lamblia in stool specimens from immunocompetent and immunocompromised children with diarrhea and other gastrointestinal symptoms.
Trial opening soon.
Get NotifiedAll sexes
Observational
Giardia duode- nalis is an intestinal protozoan parasite with a worldwide distribu- tion in human and
animals ( Dixon BR.,2021)
According to WHO reports in 2010, giardiasis is estimated to cause approximately 28.2 million cases of
diarrhea (WHO.,2015)
The prevalence of giardiasis is 2 to 5% in developed countries and 20 to 30% in developing countries in children (Luis et al.,2017)
The fecal-oral route is the main transmission mode of G. duodenalis . Drinking water, food and
vegetables contaminated by G. duodenalis cysts are the main sources of transmission ( Adam Rodney.,2021)
The common clinical manifestations of giardiasis include greasy diarrhea (steatorrhea), nausea,
vomiting, abdominal bloating, cramps, malabsorption and weight loss (Taghipour et al .,2022)
The detection and diagnosis of giardiasis present challenges for physicians, especially in regions distant
from high-prevalence areas where a substantial number of asymptomatic patients further complicate
prevalence determination. Symptoms, which closely mimic those of other parasitic diseases, can
confound clinicians, potentially leading to the prescription of ineffective remedies (Escobedo .et al .,2018)
Several different diagnostic systems have been described for the diagnosis of giardiasis: among them are
microscopic diagnosis, molecular methods, and immunoassays such as ELISA for the detection
of Giardia antigen or anti-Giardia antibodies, and Direct Fluorescence Antibody (DFA) test, which
detects antigens present on the cell wall of Giardia cysts ( Sadaka et al .,2015)
The early accurate diagnosis of giardiasis is important for the successful treatment and prevention of
diseases. The routine laboratory diagnosis is performed for the detection of trophozoites or cysts by
microscopic examination of at least three stool samples collected independently (.Uehlinger et al.,2017)
This diagnosis depends upon the times of sampling, patient compliance, application of concentration
methods, and the expertise of the technologists. Furthermore, in recent years, other methods, such as
ELIZA and molecular techniques are used mainly for diagnostic or research purposes. The sensitivity
and specificity of all diagnostic methods can be improved by including alternative diagnostic procedures
that are more rapid and reliable ( Kosack et al.,2017)
The recently licensed commercially available enzyme-linked immunosorbent assay (ELISA) kits are
found to be rapid and effective methods to diagnose Giardia infection in patients with gastrointestinal
symptomatology by detecting G. lamblia associated antigens in stool (Jahan et al.,2014)
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
evaluate the efficacy of Human anti Giardia lamblia antibody (ELISA) kitst in comparison to direct microscopy in the diagnosis of G. lamblia in stool specimens from immunocompetent and immunocompromised children with diarrhea and other gastrointestinal symptoms.
Contact information is provided by the study sponsor or research team.
Arwa yo Abdelsabour, demonstrator
CONTACT
Hanaa Ah El-Hady, Professor
CONTACT
Sohag University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04827537
Digestive System Diseases, Gastrointestinal Diseases
Tashkent, Uchtepa, Uzbekistan
View Trial DetailsNCT07358910
Adenophorea Infections, Adenoviridae Infections
Phnom Penh, Cambodia
View Trial DetailsNCT02736968
Amebiasis, Amoebic Dysentery
Dhaka, Bangladesh
View Trial DetailsNCT03490435
Adenophorea Infections, Animal Diseases
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
View Trial Details